Bricoma® Eye Drops: Each ml sterile eye drops contains Brimonidine Tartrate INN 2 mg.
Preservative: Benzalkonium Chloride solution BP 0.02%.
Brimonidine is an alpha 2 adrenergic receptor agonist which reduces aqueous humor production and increases uveoscleral outflow.
Mode of action:
Brimonidine is an alpha-2 adrenergic receptor agonist which reduces the production of aqueous humor from ciliary process. It has a peak ocular hypotensive effect occurring at two hours of post-dosing.
Brimonidine is indicated for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
The recommended dose is one drop in the affected eye(s) three times daily.
Specific drug interactions studies have not been conducted with Brimonidine eye drops.
Over dosage:
Not known.
There are no adequate and well-controlled studies in pregnant women. Brimonidine Tartrate should be used during pregnancy only if the potential benefit to the mother justifies the potential risk to the fetus. It is not known whether this drug is excreted in human milk. A decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
Caution should be exercised in treating patients with severe or unstable and uncontrolled cardiovascular disease.
Store in a cool and dry place protected from light. Keep out of reach of children. Do not touch the dropper tip to surfaces since this may contaminate the solution. Do not use after 1 month of first opening.